The Clf1p Splicing Factor Promotes Spliceosome Assembly through N-terminal Tetratricopeptide Repeat Contacts*

Qiang WangDagger , Kathryn HobbsDagger , Bert Lynn§, and Brian C. RymondDagger

From the Departments of Dagger  Biology and § Chemistry, University of Kentucky, Lexington, Kentucky 40506-0225

Received for publication, October 22, 2002, and in revised form, December 12, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Spliceosome assembly follows a well conserved pathway of subunit addition that includes both small nuclear ribonucleoprotein (snRNP) particles and non-snRNP splicing factors. Clf1p is an unusual splicing factor composed almost entirely of direct repeats of the tetratricopeptide repeat (TPR) protein-binding motif. Here we show that the Clf1p protein resides in at least two multisubunit protein complexes, a small nuclear RNA-free structure similar to what was reported as the Prp19p complex (nineteen complex; NTC) and an RNP structure that contains the U2, U5, and U6 small nuclear RNAs. Thirty Ccf (Clf1p complex factor) proteins have been identified by mass spectroscopy or immune detection as known or suspected components of the yeast spliceosome. Deletion of TPR1 or TPR2 from an epitope-tagged Clf1p protein (i.e. Clf1Delta 2-TAP) destabilizes Clf1p complexes assembled in vivo, causing the release of the Cef1p and Prp19p NTC factors and decreased association of the Rse1p, Snu114p, and Hsh155p snRNP proteins. In vitro, temperature inactivation of Clf1Delta 2p impairs the prespliceosome to spliceosome transition and prevents Prp19p recruitment to the splicing complex. These and related data support the view that the poly-TPR Clf1p splicing factor promotes the functional integration of the U4/U6.U5 tri-snRNP particle into the U1-, U2-dependent prespliceosome.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The spliceosome is composed of five small nuclear RNAs (snRNAs)1 and over 70 distinct polypeptides (reviewed in Refs. 1 and 2; see references in Refs. 3 and 4). Numerous studies have demonstrated that in vitro spliceosome assembly progresses through an ordered sequence that is largely conserved from yeast to humans. By tracking assembly through small nuclear ribonucleoprotein (snRNP) association with pre-mRNA, it has been shown that the U1 snRNP binds independently other snRNP particles in an ATP-independent step said to commit the pre-mRNA to the splicing pathway. U2 snRNP is recruited next in an ATP-dependent step that forms the prespliceosome. Finally, the U4, U5, and U6 snRNAs are jointly recruited as the exceptionally large U4/U6.U5 tri-snRNP particle to produce the spliceosome. Together, the U1/U2 snRNP-dependent prespliceosome and the U4/U6.U5 tri-snRNP particle account for all of the snRNAs and the majority of proteins known to act in splicing. A more limited number of non-snRNP splicing factors bind directly to the pre-mRNA substrate to promote snRNP addition or promote conformational changes within the splicing complex following snRNP addition (1-3).

Regulated pre-mRNA splicing events are driven by proteins that act to promote or block the recruitment of constitutive splicing factors (4, 5). The major snRNP addition steps are clear targets of this regulation. Whereas comparatively few pre-mRNAs appear regulated in yeast, this system does offer a valuable means to characterize the basic pathway for splicing factor association and hence to identify critical steps in assembly and possible targets for regulation. The addition of the U1 and U2 snRNP particles to the splicing complex occurs in part through well characterized snRNA interactions at the premRNA 5' splice site and branch point regions, respectively, and is supported by a number of protein-based contacts, reviewed in Refs. 6 and 7. The U5 and U6 snRNAs also bind the splicing substrate, although these interactions appear to occur subsequent to stable recruitment of the U4/U6.U5 tri-snRNP particle to the prespliceosome. In yeast, mutations that prevent stable U4/U6.U5 tri-snRNP assembly (e.g. Prp6p; see Refs. 8 and 9) block spliceosome formation, yet little is known in yeast or in mammals of the contacts that actually promote U4/U6.U5 tri-snRNP particle/prespliceosome association.

CLF1/SYF3 (henceforth referred to by the Stanford Genome Database standard name, CLF1) was identified as a putative Saccharomyces cerevisiae RNA-processing factor based on the presence of multiple crooked neck-like tetratricopeptide repeats (TPRs) (10). This protein binding motif was first recognized as a distinct TPR subtype in the characterization of the Drosophila melanogaster crooked neck (crn) gene product (11) and appears restricted to RNA-processing proteins (10, 12). Crooked neck and its homologs, including the yeast Clf1p protein, are ~80 kDa in mass and composed largely of direct iterations of the TPR motif. Loss of function crooked neck mutations in Drosophila are lethal when homozygous (11) (and references within) and influence alternative splice site selection when heterozygous (13). In humans, the crooked neck protein is a stable component of the spliceosome, recruited at or near the time of U4/U6.U5 tri-snRNP addition (14). In yeast, genetic and biochemical studies implicate Clf1p in a number of steps in spliceosome assembly and in both catalytic steps in splicing (10, 15-18). This broad spectrum of Clf1p interactions is consistent with the 15 TPR repeats of Clf1p serving as a platform for the recruitment of splicing factors during spliceosome assembly.

Clf1p is present in the nineteen complex (NTC), a structure that contains Prp19p and at least eight other proteins but no RNA (see Ref. 18 and references within) (19). Yeast extracts metabolically depleted of Clf1p block the prespliceosome to spliceosome transition even in the presence of stable U4/U6.U5 tri-snRNP complexes (10), suggesting that Clf1p acts in the recruitment or retention of the U4/U6.U5 tri-snRNP particle. Curiously, whereas Clf1p functions prior to stable spliceosome formation, the NTC is reported to bind the splicing complex later, during or after the U4 snRNA release from the mature spliceosome (20). This inconsistency and results from the Schizosaccharomyces pombe system that cast doubt on the RNA-free status of the NTC (21) stimulated a detailed analysis of Clf1p function in the spliceosome assembly pathway.

The genetic and biochemical data presented here show that Prp19p and Clf1p reside in at least two resolvable states, a complex free of snRNA similar to the NTC and an RNP complex reminiscent of an endogenous late stage or postcatalytic spliceosome. Removal of TPR elements from the Clf1p amino terminus results in the conditional release of several essential splicing factors and blocks the recruitment of Prp19p to the splicing apparatus. These observations provide evidence that the N-terminal TPR elements of Clf1p recruit splicing factors required for the successful integration of the two large RNP halves of the spliceosome.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Yeast Strains and Plasmids-- Details on the construction of the clf1::HIS3 yeast deletion mutant and the GAL1::clf1(697), Ycplac22-CLF1-HA, and Ycplac22-clf1Delta 2 plasmid constructs were previously published (10). Ycplac22-clf1Delta 1 was prepared similarly by inverse PCR with oligonucleotides Delta 1-1 and Delta 1-2 (Table I). The TAP epitope was amplified from plasmid pBS1479 (22) with oligonucleotides TAP1 and TAP2 and blunt end-ligated into a SnaBI site created by PCR mutagenesis (with oligonucleotides SNA1 and SNA2) at the 3'-end of the CLF1 coding sequence. The Ycplac22-CLF1-TAP and deletion constructs were transformed into SY101 yeast (MATa, ura3-53, lys2-801a, ade2-101, trp1Delta 1, his3-Delta 200, leu2-Delta , clf1::HIS3, pSY1[GAL1::clf1(679), URA3], selected on galactose-based complete medium without tryptophan (23). Subsequent assays for mutant gene activity were done on YPD medium made with 2% glucose or on complete medium with 1 µg/ml 5-fluoroorotic acid (24). Haploid stains deleted for ISY1, SYF2, ECM2, and NTC20 were obtained from the ATCC (Manassas, VA). CLF1-TAP was transformed into this mutant set as a XbaI-SphI DNA fragment cloned into the URA3-marked plasmid, Ycplac33 (25).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Oligonucleotides used in this study

PRP46 was amplified from genomic DNA with oligonucleotides 46-1 and 46-2 and cloned into Ycplac111 (25). The TAP PCR fragment was inserted into a SmaI site engineered in the 3'-end of the PRP46 coding sequence. The Ycplac111-PRP46-TAP plasmid was transformed into yeast heterozygous for a PRP46 deletion obtained from the ATCC. Haploid strains that exclusively expressed the plasmid-borne PRP46-TAP allele were isolated from meiotic offspring.

Splicing and Spliceosome Assembly Assays-- The analysis of cellular pre-mRNA splicing was conducted as described (26). To deplete Clf1p from yeast, the GAL1::clf(697) strain was grown to early log phase in galactose-based YP medium (23), harvested by centrifugation, washed with 1 culture volume of sterile water, and then incubated in glucose-based YP medium for 6-8 h. Splicing extracts were prepared by grinding yeast cell pellets in liquid nitrogen as described (27). Pre-mRNA substrates were prepared by in vitro transcription of pSPrp51A (RP51A) (28) or pT7Delta 2 (rp51Delta 2) (29) with nucleotide triphosphates including [32P]UTP or biotin 16-UTP (Roche Molecular Biochemicals) and a 5-fold molar excess of cap analog (New England Biolabs). Streptavidin-agarose affinity purification of spliceosomes and snRNA analyses were performed as described (30) scaled down to an 80-µl splicing reaction. Spliceosome assembly was assayed by native gel electrophoresis, and pre-mRNA splicing was assayed by denaturing gel electrophoresis as described (31). Clf1Delta 2-TAP extracts were temperature-inactivated by incubation at 37 °C for 5 min or at 34 °C for 30 min and used without additional manipulation. Complementation experiments were performed by incubation of 50-100,000 cpm of labeled pre-mRNA substrate with the temperature-inactivated extract for 5 min under splicing conditions in a volume of 8.5 µl followed by the addition of 1.5 µl of Clf1p complex (approximately 3 ng of protein) together with a 50-fold molar excess of unlabeled pre-mRNA.

Clf1-TAP, clf1Delta 1-TAP, clf1Delta 2-TAP, and Prp46-TAP Purifications-- To isolate preparative quantities of the Clf1-TAP complex, 50 liters of yeast were harvested by centrifugation at an A600 of 2-3. The cell pellets were washed twice with 2 liters of sterile water and resuspended in 500 ml of buffer A (10 mM Hepes, pH 7.9, 10 mM KCl, 200 mM NaCl, 0.5 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 2 mM benzamidine, 0.5% Nonidet P-40). The yeasts were frozen in liquid nitrogen and then broken in a Waring blender as described (32). The lysate was cleared by centrifugation at 20,500 rpm in a Beckman Ti45 rotor for 30 min followed by 84 min at 33,500 rpm in a Beckman Ti45 rotor. The cleared lysate was then dialyzed against buffer D (10 mM Hepes, pH 7.9, 50 mM KCl, 0.5 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 2 mM benzamidine, 20% glycerol) for 3 h. The extract was adjusted to 200 mM NaCl, 0.1% Nonidet P-40 immediately prior to TAP affinity purification, performed as described (22), except that 2 ml of rabbit IgG agarose (Sigma) was used for 500 ml of lysate. Analytical scale preparation of 35S-labeled TAP complexes was performed by adding 1 mCi of Trans-35S (ICN) to the equivalent of 10 ml of culture at an A600 of 1.0 for 4-5 h at 30 °C as described (33). For temperature shifts, the clf1Delta 1-TAP and CLF1-TAP cultures were incubated to 37 °C for the final 1 h of labeling. The cell pellets were collected by centrifugation and washed once with water, and proteins were extracted by vortexing the pellet for 4 min with glass beads in buffer A. TAP purification was then performed as described (22), scaled down for use with the reduced volumes. Where indicated, NaCl was increased to 300 or 450 mM before cell breakage. RNase-treated samples were incubated at room temperature for 15 min with 22 µg/ml RNase A and 444 units/ml of RNase T1 (Ambion) prior to TAP purification. The recovered protein samples were precipitated with 6% trichloroacetic acid, resolved on a 5-10% gradient (or 8% nongradient) SDS-polyacrylamide gel with BenchMarkTM molecular weight markers (Invitrogen), and visualized with a Typhoon PhosphorImager (Amersham Biosciences). Alternatively, the samples were fractionated on a 15-40% glycerol gradient prepared in 50 mM Tris-HCl, pH 7.4, 20 (or 200) mM NaCl, and 5 mM MgCl2 prior to protein and snRNA analyses.

Mass Spectrometry-- The purified Clf1-TAP complex sample was resolved on a 5-10% gradient SDS-polyacrylamide gel in a Tris-Tricine buffer system (34). After electrophoresis, the gel was stained with silver (35), and the protein-containing bands were excised and digested with trypsin (36). The tryptic peptides were fractionated with a Luna C18 (1 × 50 mm, 3-µm particle size) column (Phenomenex, Torrance, CA) using an acetonitrile/water (0.1% formic acid) gradient at a flow rate of 35 µl/min. The LC column was connected to the electrospray interface of an LCQ Classic mass spectrometer (ThermoFinnigan, San Jose, CA). Mass spectra were acquired using data-dependent analysis (full scan automatically followed by tandem mass spectrometry of the most intense ion detected by the data system). Alternatively, the Clf1-TAP complexes were assayed by DALPC without gel fractionation using strong cation exchange and C18 (Whatman) packing material on a LCQ Deca mass spectrometer (ThermoFinnigan, San Jose, CA). In all cases, the tandem mass spectra were converted to mass/intensity lists and searched against the nonredundant OWL data base using SEQUEST and the nonredundant NCBI data base using MASCOT. The number of unique peptides identified for each protein was as follows: Clf1p, 26; Prp8p, 21; Brr2p, 10; Rse1p, 3; Snu114p, 5; Hsh155p, 4; Syf1p, 22; Cef1p, 26; Prp28p, 2; Prp19P, 14; Prp46p, 6; Prp45p, 4; Cwc2p, 3; Cwc23p, 4; Ecm2p, 4; Isy1p, 5; Smb1p, 2; Syf2p, 2; Snt309p, 8; Smd1p, 3; Ntc20p, 4; Smd2p, 7; Smd3p, 3; Lsm2p, 1; Sme1p, 1; Smx3p, 1; Prp22p, 13; Cus2p, 2. Proteins without confirmed links to splicing that co-purified with Clf1-TAP in one or more preparations include Aad15p, Adh1p, Ade6p, Bud31p, Cin8p, Imp2p, Lem3p, Nop1p, Pdc1p, Ptc7p, Rgd2p, Rpl8ap, Rlp18bp, Rlp24p, Rpl28p, Rpl15p Rpl18bp, Rps14p, Rps19ap, Rpl24p, Rps17p, Rps13p, Rpl13p, Rps6p, Scc2p, Smc3p, Ssa2p, Ssa4p, Sum1p, Tef2p, Tdh1p, Tdh3p, Ulp1p, Zms1p, and the product of open reading frames YGL034C, YKR022C, YIL080W, and YLR424W.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Clf1p Resides in at Least Two Distinct Multisubunit Complexes-- To learn more of Clf1p function in spliceosome assembly, proteins associating with this essential splicing factor were purified from yeast. As a first step, Clf1p was modified to include a TAP affinity cassette (22) at the nonessential C terminus (10). The CLF1-TAP strain and a negative control strain that expresses a hemagglutinin (HA)-tagged protein that does not bind the TAP affinity resin were labeled with [35S]methionine and cysteine for 4 h prior to tandem affinity purification. PAGE analysis reveals numerous proteins present in the Clf1-TAP but absent in the Clf1-HA control sample (Fig. 1A). Thirty of the Ccf (Clf1p complex factor) proteins were identified as known or suspected splicing factors by mass spectroscopy (Table II). In several cases, two or three Ccf proteins co-migrate in a single band, leading to an underestimation of the number of Ccf factors by one-dimensional electrophoresis. The validity of the Ccf assignments was spot-checked with antibodies against specific proteins and through the use of gene-specific deletion strains (Table I; see "Experimental Procedures"). For the sake of consistency, the established nomenclature will be used for all previously identified Ccf splicing factors.


View larger version (94K):
[in this window]
[in a new window]
 
Fig. 1.   Clf1p-bearing protein complexes. A, proteins from 35S-labeled yeast cultures were purified by TAP selection and resolved by PAGE. Clf1-HA does not bind the TAP affinity resins; consequently, proteins found in this lane represent nonspecific background. Proteins enriched by affinity selection are labeled Ccf (for Clf1p complex factors). The numbers at the left indicate the masses in kDa of protein standards. B, affinity-purified Clf1p complex fractionated on a 15-40% glycerol gradient. Ccf proteins not clearly resolved in the unfractionated sample (T) are shown on the right. Bands corresponding to Cef1p (Ccf7p) and Syf2p (Ccf17p) label poorly and were not observed in this experiment. The fractions containing nonspecific (NS) proteins, the Clf1p-NTC, and the Clf1p-RNP fractions enriched in U5 and U6 proteins (Clf1p-(U2), U5, U6) and U2, U5, and U6 proteins (Clf1p-U2, U5, U6) are indicated below. Where two or more proteins are believed to co-migrate only a single protein is labeled, and this is marked with an asterisk (although it is possible that not all proteins are present in each gradient fraction). The sedimentation coefficients presented correspond to the U6 snRNP (7 S), thyroglobulin (19 S), the U4/U6.U5 tri-snRNP particle (25 S), and the 40 and 80 S ribosomal particles. The migration of proteins in the input sample (T) is somewhat distorted by a gel artifact relative to fraction 1. C, Western blot of total cellular protein resolved on a 15-40% glycerol gradient and probed with IgG to identify Clf1-TAP. D, Northern analysis of snRNA from whole cell lysate resolved on a 15-40% glycerol gradient. Lane T, total, unfractionated RNA. The peak positions of the previously identified snRNP complexes are indicated below.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Ccf protein identities

In order to investigate the subunit diversity of the Clf1p complex(es), the 35S-labeled affinity-purified proteins were resolved on a 15-40% glycerol gradient, and alternate fractions were compared (Fig. 1B; note, for clarity, where multiple proteins are present in a single band, only one is labeled). Fraction 1 contains mostly background proteins, a pattern similar to that observed with the control extract in Fig. 1A. Superimposed on this pattern in fraction 3 and extending through fraction 11 are Clf1p, Syf1p, Ccf8p, Prp19p, and Isy1p (but presumably not the co-migrating Lea1p protein; see snRNA analysis, discussed below). Cef1p co-migrates with Clf1p at ~84 kDa (due to the presence of residual TAP sequence) but can be resolved with the use of Clf1p TPR deletion mutants or when an alternatively tagged strain is used for purification (see below). Other than the undetectable levels of certain low molecular weight proteins that label poorly (e.g. Syf2p and Snt309p), this banding pattern closely resembles that of the NTC and will be referred to as the Clf1p-NTC to designate the protein used for purification. Two unidentified proteins, Ccf8p, which may be equivalent to Ntc81p (37), and a previously unreported protein of ~220 kDa (Ccf25p) are also present in these fractions. A small amount of Prp8p and Brr2p are reproducibly observed in this region of the gradient as well. The Sm/Lsm core snRNP proteins are absent in fractions 1-11.

With the intriguing exception of Ccf8p, the Clf1p-NTC complex proteins become markedly enriched in fractions 13-15. Here too are the U5-snRNP-associated proteins Prp28p and Snu114p (as well as Prp8p and Brr2p), Prp46p, the co-migrating Prp45p/Slu7p and Cwc2p/Cwc23p/Ecm2p protein sets, the uncharacterized protein Ccf14p, the Sm/Lsm proteins, and four protein bands not observed prior to gradient separation (Ccf25p-Ccf28p; see Table II). Ccf26p has been identified by Western blot as Prp22p, a protein that interacts genetically with Clf1p and other components of the Clf1p-RNP complex (16, 38). In addition to the mentioned proteins, fractions 17-23 also contain the U2 snRNP-specific proteins Rse1p and Hsh155p, presumably Lea1p, the Ccf29p band (Cus2p), and factors found in the lighter snRNP-enriched gradient fractions. Of the proteins identified by mass analysis, only Prp16p was not observed as an obvious gel band. The Clf1p profile from whole cell extract (Fig. 1C) is similar to that of the purified complex with discreet pools in the lower and upper regions of the gradient, although the high concentration of total protein in fractions 3-5 partially inhibits Clf1p transfer (see Fig. 2E for a related image). The presence of Clf1-TAP in fractions 7-11 of the whole cell extract argues against the Clf1p-NTC arising from dissociation of the larger complex during the lengthy affinity purification steps. The Clf1-TAP peak enriched for U2 as well as U5 and U6 snRNP proteins (Fig. 1, B and C, roughly fractions 17-19) overlaps the position of the U4/U5.U6 snRNP particle (Fig. 1D) and corresponds to a complex of ~40 S. 


View larger version (52K):
[in this window]
[in a new window]
 
Fig. 2.   Spliceosomal snRNAs co-purify with Clf1p. A, the TAP-specific Ccf bands are shown with proteins released from the complex by RNase treatment indicated by solid bars at the right. Where multiple proteins co-migrate, only one is labeled and indicated by an asterisk. B, complexes isolated by TAP purification from Clf1-TAP yeast and a Clf1-HA negative control strain were probed for the U1, U2, U4, U5, and U6 spliceosomal snRNAs. Total, total unfractionated extract; Unbound, RNA remaining in the supernatant after immune precipitation; Bound, RNA present in the immune pellet. Approximately 2% of the total and unbound samples were loaded relative to the immune pellet. C, Western blot of Clf1-TAP present in cell extract (Total), recovered by tandem affinity purification (Bound), and remaining in the supernatant (Unbound) resolved on an 8% polyacrylamide/SDS gel. D, Clf1-TAP whole cell extract was fractionated on a 15-40% glycerol gradient, and alternate fractions were assayed for snRNA content after immune precipitation with IgG. RNA from the total unfractionated extract (T) is compared with the immune pellets numbered from the top of the gradient tube. E, mouse IgG was used to immune precipitate Clf1-TAP from alternative gradient fractions. The immune pellets were then probed with the anti-Prp19p polyclonal antibody that binds the TAP epitope of Clf1-TAP as well as Prp19p. F, glycerol gradient fractions 1, 4, 7, 10, and 17 were immune precipitated with the alpha -Prp19p antibody and assayed by Western blot for Prp19p. Affinity-purified Clf1-TAP complex is presented in the first lane (Complex) for comparison. Ab, the alpha -Prp19p antibody.

The Clf1p-RNP Complex-- A subset of the known U2 and U5 snRNP proteins co-purify with the Clf1p complex. Recently, Cef1p-bearing multi-snRNP complexes were reported to be RNase-resistant (39). In contrast, treatment of the Clf1-TAP extract with RNase A and T1 prior to purification causes release of Lsm2p, Smb1p, Smd2p, Sme1p, and Smx3p core snRNP proteins and a reduction in the Smd1p/Ntc20p band intensity (Fig. 2A). Multiple other proteins, including the U2- and U5-specific snRNP proteins, remain Clf1-TAP-associated. The RNase treatment regime used degrades all snRNA detectable by Northern blot (data not shown). Consequently, it appears that snRNA contacts stabilize core snRNP protein association with the Clf1p complex, whereas the bulk of the remaining components associate though protein-based contacts. It is possible, however, that small RNA fragments persist in the Clf1p complex and contribute to this stabilization.

Consistent with the snRNP protein composition, the U2, U5, and U6 snRNAs (but not U1 or U4 snRNA) are enriched in the affinity-purified Clf1-TAP complexes (Fig. 2B). Nonspecific binding to the TAP affinity resin is very low, since no detectable snRNAs are recovered with a control extract that lacks a TAP-tagged protein (i.e. Clf1-HA). The bulky TAP epitope enhances snRNA recovery, since previous experiments performed with alternative CLF1 alleles failed to recover snRNA (10) or recovered no U2 snRNA and nearly background levels of U5 and U6 snRNA (15). The amount of snRNA recovered with Clf1-TAP is less than what is commonly observed with snRNP-specific proteins, however. Soluble Clf1-TAP protein recovery is typically 30-70% (Fig. 2C), and only 2-5% of the U2, U5, and U6 snRNAs co-purify.

As shown above, the Clf1p present in whole cell lysates distributes broadly across a 15-40% glycerol gradient. When these gradient fractions are used for immune precipitation, the majority of Clf1-TAP-associated snRNA is recovered from the poly-snRNP fraction (fractions 15-19) with no detectable free U6 snRNP (Fig. 2D, fractions 5-7; see Fig. 1D) and little if any U4/U6 di-snRNP (fractions 9-11), or free U2 snRNP or U5 snRNP (fractions 7-13) precipitating. This recovery pattern indicates that Clf1p does not bind individual snRNP complexes but resides in a more complex RNP structure. Curiously, whereas Prp19p is reported as predominately RNA-free in extracts (see Ref. 18 and references within) (19), both Clf1-TAP and Prp19p are recovered from the RNP fractions with antibodies against the TAP epitope (Fig. 2E). This apparent discrepancy was resolved when representative gradient fractions were reassayed with the anti-Prp19p antibody. In this case, Prp19p is efficiently recovered from gradient fractions with little snRNA (other than U6) is present (e.g. Fig. 2F, factions 4 and 7; see Fig. 1D) but poorly from the snRNP-containing fractions (e.g. fractions 10 and 17). As with the earlier reports, no snRNA was recovered with the anti-Prp19p antibody (data not shown). Thus, whereas Clf1p and Prp19p reside within RNA-free and RNP complexes, the RNP structure inhibits Prp19p recovery by immune precipitation.

Influence of TPR Structure on Clf1p Complex Integrity-- Yeast with deletions of the first or second Clf1p TPR repeat have growth and splicing defects that become more pronounced at elevated temperatures, presumably due to changes in Clf1p stability or activity (10) (data not shown). To investigate protein abundance, lysates from CLF1-TAP, clf1Delta 1-TAP, and clf1Delta 2-TAP cultures were assayed by Western blot before and after shift to the restrictive temperature. Clf1-TAP and the deletion derivatives co-migrate on this minigel system and are found at similar levels (Fig. 3A). In addition to the full-length proteins, a protein ~20 kDa smaller is present in each sample but absent in an untagged extract (Fig. 3A and data not shown). The levels of this putative decay intermediate vary between extract preparations but are reproducibly greater with the TPR deletion strains. Nevertheless, as the full-length Clf1p (or TPR deletion derivative) levels decrease only slightly with temperature shift, it is unlikely that splicing inhibition observed in the clf1Delta 1-TAP or clf1Delta 2-TAP cultures results from lower Clf1p abundance. Furthermore, clf1Delta 1-TAP and clf1Delta 2-TAP are recessive mutations and do not act as dominant negative inhibitors of splicing. By this measure, it appears that the N-terminal deletion derivatives of Clf1p are stable but less active in splicing.


View larger version (79K):
[in this window]
[in a new window]
 
Fig. 3.   N-terminal TPR deletions destabilize Clf1p complexes. A, Western analysis of yeast proteins from CLF1-TAP, clf1Delta 1-TAP, and clf1Delta 2-TAP cultures grown continuously at the permissive temperature (30 °C) and after a 2-h shift to the restrictive temperature (37 °C). The positions of the putative N-terminal degradation products are indicated with an asterisk. B, 35S-labeled Clf1p complexes were isolated in 200, 300, and 450 mM NaCl and resolved on a 5-10% polyacrylamide/SDS gel. Proteins that show enhanced salt sensitivity due to the Clf1Delta 2-TAP mutation are indicated by bars at the right. The asterisks indicate where two or more Ccf bands co-migrate. The overall darker band intensities in the lower salt Clf1Delta 2-TAP cultures reflect minor experimental variation in the labeling efficiency. C, 35S-labeled proteins from Clf1-TAP and Clf1Delta 1-TAP complexes isolated from cultures shifted to 37 °C for 1 h prior to harvest. The positions of the Clf1Delta 1p and the Clf1Delta 1p degradation products are indicated on the right, and proteins that show enhanced temperature sensitivity with the Clf1Delta 1-TAP mutation are indicated by an asterisk. D, 35S-labeled proteins from a wild type Prp46-TAP culture isolated at 200, 300, and 450 mM NaCl. The positions of Prp46p, the temperature-sensitive proteins, and the stably bound but co-migrating Clf1p/Ccf8p proteins are indicated at the right.

TAP affinity purification was repeated at different salt concentrations to learn whether the N-terminal TPR deletions described above destabilize the Clf1p complexes (Fig. 3B). For the wild type Clf1-TAP complex, the recovered protein set is equivalent at 200 and 300 mM NaCl and shows reduced levels of selected proteins at 450 mM NaCl. With the Clf1Delta 2-TAP complex, the Cef1p and Prp19p proteins are reproducibly more sensitive to dissociation at 300 and 450 mM NaCl. Since Cef1p co-migrates with Clf1p, Cef1p release was monitored with complexes isolated using a Prp46-TAP construct (Fig. 3D). The pattern of recovered proteins is nearly identical with Clf1-TAP and Prp46-TAP, but when Prp46-TAP is used Clf1p and Cef1p are well resolved. Cef1p remains stably bound at 450 mM NaCl in the wild type complex but fully dissociates from the Clf1Delta 2-TAP complex at 300 mM NaCl.

Rse1p and Hsh155p are sensitive to dissociation at 450 mM NaCl in the wild type extracts (Fig. 3B) and missing from gradient fractions 13-15 of the Clf1p-RNP even under low salt conditions (see Fig. 1B). Even so, Rse1p, Hsh155p, and Snu114p appear more sensitive to dissociation in the Clf1Delta 2-TAP complex (Fig. 3B). Rse1p, Hsh155p, Cef1p, Prp19p, and to a lesser degree Snu114p are also more readily dissociated from the Clf1Delta 1-TAP complex isolated from yeast shifted to the restrictive temperature of 37 °C prior to harvest (Fig. 3C). Therefore, the splicing defects resulting from the N-terminal TPR deletions are correlated with the selective loss of both snRNP and non-snRNP components from Clf1p complexes. Importantly, all of the Clf1Delta 1-TAP/Clf1Delta 2-TAP-sensitive proteins are essential; the failure to properly assimilate any one into the spliceosome would probably block pre-mRNA splicing.

Clf1Delta 2-TAP Inactivation Inhibits the Productive Addition of the U4/U6.U5 to the Prespliceosome-- To investigate the nature of the Clf1Delta 2-TAP splicing defect, extracts were prepared from Clf1Delta 2-TAP yeast and assayed for spliceosome assembly and splicing in vitro. Extract prepared at the permissive temperature supports spliceosome assembly on RP51A pre-mRNA through the previously described prespliceosome (complex III), precatalytic spliceosome (complex I), and spliceosome (complex II) states (31) (Fig. 4A). In contrast, when this extract is briefly preincubated at the restrictive temperature, spliceosome assembly stops at the prespliceosome stage. As expected, the untreated sample supports pre-mRNA splicing (Fig. 4B), whereas the temperature-inactivated sample does not (lanes 1 and 2). Splicing is restored by the addition of purified Clf1p complex in the presence of saturating amounts of unlabeled pre-mRNA substrate. This amount of cold competitor blocks de novo assembly on labeled pre-mRNA (lane 5). Consequently, the splicing complexes formed in the Clf1Delta 2-TAP inactive extract, while incomplete, are functional and can be chased through the splicing pathway. The Clf1p complex itself does not support pre-mRNA splicing (lane 4), and the inactivation conditions do not impair splicing or spliceosome assembly in wild type extracts (e.g. Refs. 30 and 40; data not shown). Accordingly, conditions that destabilize the Clf1Delta 2-TAP complex structure inhibit the productive recruitment of the U4/U6.U5 tri-snRNP particle to the prespliceosome.


View larger version (50K):
[in this window]
[in a new window]
 
Fig. 4.   Temperature inactivation of Clf1Delta 2-TAP blocks splicing and impairs spliceosome assembly. A, time course of spliceosome assembly on 32P-labeled RP51A pre-mRNA incubated in Clf1Delta 2-TAP extract maintained at 23 °C (-) or shifted to 37 °C (+) for 5 min prior to substrate addition. The bands corresponding to the prespliceosome (III), the snRNP complete spliceosome (I), and the spliceosome after U4 snRNA dissociation (II) are indicated at the left. B, assay of RP51A pre-mRNA splicing in the Clf1Delta 2-TAP extract before heat inactivation (lane 1) and after heat inactivation in the presence (lane 3) and absence (lane 2) of purified Clf1p complex. Complementation was performed by preincubating the labeled pre-mRNA with the heat-denatured extract for 5 min followed by the addition of cold RNA. Lane 4 contains purified complex incubated with pre-mRNA under standard splicing conditions. In lane 5, the labeled and unlabeled RNAs were premixed and added directly to the Clf1Delta 2-TAP extract. The positions of the lariat intermediate (LI), excised intron (I), pre-mRNA (P), mRNA (M), and released 5' exon (5'E) are indicated. In order to resolve the very small 5' exon RNA, the samples were run a second time on a higher percentage polyacrylamide gel, imaged, and inserted below the solid bar at the bottom.

Clf1p Is Required for Prp19p Recruitment to the Spliceosome-- The results presented above show that brief heat treatment destabilizes the Clf1Delta 2-TAP complex and impairs spliceosome formation. It was not clear, however, whether proteins released from the Clf1Delta 2-TAP complex could be independently bound by the splicing complex. To address this, splicing complexes were assembled in vitro with or without active Clf1p and then assayed for the presence of the essential Prp19p maturation factor. Biotin-substituted RP51A pre-mRNA was incubated in extract for 30 min under splicing conditions, and then the assembled complexes were recovered by streptavidin chromatography. Bands corresponding to Clf1-TAP and Prp19p were observed in complexes assembled with the splicing-competent Clf1-TAP extract (Fig. 5A, lanes 1 and 2). The spliceosome association of Prp19p requires Clf1p function, however, since metabolic depletion of Clf1p by transcriptional repression of the GAL1::clf1(697) fusion gene (lane 5; see "Experimental Procedures") blocks Prp19p recovery. Unfortunately, a nonspecific protein enriched on the streptavidin matrix co-migrates with Clf1-TAP and is bound by the Prp19p antibody. This band is prominent in all samples including controls where the pre-mRNA lacks biotin (lane 4) and where no TAP-tagged protein is present (lane 5). To circumvent this problem, Clf1p association with the spliceosome was tested by probing the recovered protein with a TAP-specific antibody (lanes 11-13) and through the use of the Clf1Delta 2-TAP derivative, which migrates ahead of the background band (lanes 7-10). Similar to what was observed with the Clf1p-depleted samples, temperature inactivation of Clf1Delta 2-TAP blocks Prp19p association. Equivalent results were observed with an alternate splicing-competent splicing substrate, rp51Delta 2 (lanes 3, 6, 8, and 10; see "Discussion"). Curiously, under conditions where Prp19p recruitment to the spliceosome is blocked, Clf1Delta 2-TAP still associates with the splicing complex (compare lanes 7 and 8 with lanes 9 and 10).


View larger version (68K):
[in this window]
[in a new window]
 
Fig. 5.   Temperature inactivation of Clf1Delta 2-TAP activity blocks Prp19p recruitment to the spliceosome but not its own association. A, Western blot of immune precipitated TAP complex (lanes 1 and 11) and spliceosomes recovered with biotin-labeled pre-mRNA (lanes 2, 3, 5-10, 12, and 13) or with a no-biotin control substrate (lane 4). Splicing complexes were assembled in wild type extract (lanes 2-4 and 12), extract metabolically depleted of Clf1p (lanes 5, 6, and 13), and Clf1Delta 2-TAP extract before (lanes 7 and 8) and after (lanes 9 and 10) temperature inactivation. NS, a nonspecific band enriched by streptavidin chromatography and bound by the anti-Prp19p antibody. Samples present in lanes 1, 2, and 5 were rerun in lanes 11-13 and probed with mouse protein A followed by an alkaline phosphatase-conjugated goat anti-mouse antibody that does not detect the background band. B, in vitro splicing reactions were assembled before or after temperature shift (23 and 37 °C, respectively) on radiolabeled RP51A pre-mRNA and then immune precipitated with mouse IgG agarose. This antibody binds the TAP epitope present in samples 1-8 but missing in the untagged control (lanes 9 and 10). T, total unfractionated RNA; IP, immune pellet; LI, lariat intermediate; I, circular excised intron; P, pre-mRNA; M, mRNA; 5'E, upstream exon. The asterisk marks the position of the linear excised intron that can be seen in several lanes.

When radiolabeled pre-mRNA is used for in vitro splicing, lariat intermediate, excised intron, and low levels of pre-mRNA are recovered with the anti-TAP antibody from wild type extracts with or without heat treatment (Fig. 5B). The presence of pre-mRNA in the complex shows that Clf1p resides in the precatalytic spliceosome, whereas the absence of mRNA shows that Clf1p persists at least through the Prp22p-dependent step of mRNA release. The same RNA species are recovered with the Clf1Delta 2-TAP extract when maintained at 23 °C (albeit at lower levels). Heat inactivation of Clf1Delta 2-TAP prevents splicing but, as noted above, does prevent this protein from associating with splicing complexes. Consistent with this, the amount of RP51A pre-mRNA present in the heat-treated Clf1Delta 2-TAP complex (lane 8) is well above the background (lane 10) and equal to or greater than that found in the splicing competent extracts (lanes 2, 4, and 6). Together these data show that the Clf1p is a stable constituent of the spliceosome and demonstrate that the N-terminal TPR domain of Clf1p is required for recruitment of the essential Prp19p splicing factor to the yeast splicing apparatus.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Premessenger RNA splicing is an amazingly faithful process given the limited information content of splice site consensus sequences. Stepwise spliceosome assembly may offset the limitations of restricted sequence conservation, since this process advances only when previously bound factors are present in the correct position, orientation, and spacing. Whereas the recent identification of unexpected poly-snRNP complexes and interactions (e.g. see Refs. 41-44) suggests that the details of spliceosome assembly may be less rigidly constrained than formerly envisioned, the basic view that substrate selection is context-dependent and occurs through a dynamic process of splicing factor association is very likely correct. Here we show that the poly-TPR protein, Clf1p, plays a critical role in the union of the two large RNP "halves" of the spliceosome, namely the U1/U2-dependent prespliceosome and the U4/U6.U5 tri-snRNP particle. Whereas inactivation of the yeast U4/U6.U5 tri-snRNP protein, Prp31p (45), or the removal of the mammalian SR-like U4/U5.U6 tri-snRNP protein sp110/START1 or p65 (46) blocks spliceosome formation, to our knowledge this is the first example of a non-snRNP yeast splicing factor influencing the prespliceosome to spliceosome transition.

The Clf1p-NTC contains proteins previously reported in the Prp19p-NTC (see Ref. 18 and references within) (19), uncharacterized proteins of ~74 kDa (Ccf8p) and 220 kDa (Ccf25p), and, surprisingly, low levels of the normally snRNP-associated Prp8p and Brr2p. In addition to residing in the NTC state, Clf1p and Prp19p are also present in the Clf1-RNP. The presence of Prp19p in this RNP complex provides explanation for earlier observations that U6 snRNA levels decrease and "free" U4 snRNA levels increase after prp19-1p inactivation, characteristics tightly correlated with the perturbation of U6-bearing snRNP complexes (26, 47). The Clf1p-RNP is refractory to precipitation with an antibody against Prp19p, consistent with the inability of this antibody to deplete Prp19p activity from extracts (19) and accounting for the earlier suggestion that Prp19p exists largely in an RNA-free state in cell extracts (19, 20). Prp19p does not appear to bind Clf1p directly, and of the many protein-protein interactions identified among Clf1p-NTC components only Cef1 binds both Prp19p and Clf1p (18). Since Prp19p and Cef1p interact in two-hybrid and far Western assays (37) and, as shown here, dissociate in parallel from Clf1Delta 1-TAP or Clf1Delta 2-TAP inactivated complexes, Cef1p is a prime candidate for a protein that tethers Prp19p to Clf1-NTC.

In contrast to what was recently reported for related Cef1p/Cdc5p RNP complexes (21), we find that the Clf1-RNP is RNase-sensitive, since all detectable core snRNP proteins are released by this treatment. Many factors do remain bound to Clf1p after RNase digestion, however, showing that the Sm and Lsm proteins do not provide extensive stabilizing contacts. In addition to the majority of proteins present in Cef1p/Cdc5p RNP complexes, we observe the Prp16p and Prp28p DExD/H-box proteins, Sme1p, and the Lsm2p core snRNP protein in the Clf1p-RNP. The relative Clf1p-NTC/Clf1p-RNP abundance is highly reproducible in S. cerevisiae, and we have observed nothing to indicate that the Clf1p-RNP complex can be dissociated into the RNA-free state by simple manipulation of salt or temperature. Curiously, no equivalent to the RNA-free NTC was found in fission yeast Cdc5p complexes (39). Given the conservation of the spliceosome assembly pathway, we think it unlikely that Clf1p-NTC exists in budding yeast but not in fission yeast. Rather, the steady state abundance of this RNA-free NTC complex may be lower in the fission yeast, or Cdc5p may preferentially associate with the RNP form of this complex in S. pombe.

Pre-mRNA, splicing intermediates, and excised intron co-precipitate with Clf1-TAP, supporting genetic and biochemical studies that suggest Clf1p-associated proteins act from the earliest stages of spliceosome assembly (e.g. Mud2p and Prp40p) through the final step in splicing and product release (e.g. Prp16p, Prp17p, and Prp22p) (see Refs. 10, 15-18, and 38 and references within). Cheng and co-workers (20) report that Prp19p binds spliceosomes with or soon after the release of U4 snRNA. This conclusion appears inconsistent with the observations that Prp19p requires Clf1p to bind the spliceosome and that the removal of Clf1p activity impairs stable association of the U4/U5.U6 tri-snRNP particle. A possible trivial explanation for this discrepancy is that Prp19p is present in earlier complexes but, similar to what was found with the Clf1p-RNP, is not antibody-accessible. We do find, however, that whereas assembly is arrested at the prespliceosome stage with RP51A pre-mRNA, certain other pre-mRNAs, including the rp51Delta 2 deletion derivative used here assemble snRNP-complete but catalytically inactive splicing complexes in the absence of Clf1p. This shows that the prespliceosome and U4/U5.U6 tri-snRNP can interact, albeit nonproductively, in the absence of Clf1p. And whereas the molecular basis of pre-mRNA substrate discrimination is unknown, the rp51Delta 2 arrest point shows that Clf1p is also needed after the stable addition of the U4/U6.U5 tri-snRNP addition, a time when Prp19p is proposed to function. We note that Prp19p fails to stably bind to the spliceosome when Clf1Delta 2-TAP is inactivated even with substrates that permit spliceosome formation, for example, rp51Delta 2 (see Fig. 5A). Consequently, the rp51Delta 2 arrest point reflects, at least in part, a defect in Prp19p recruitment.

Abelson and colleagues (42) have reported the isolation from yeast of a complex containing all five snRNAs. The "penta-snRNP" protein constitution is evocative of a splicing complex prior to substrate association. The A (prespliceosome), B (spliceosome), and C (splicing intermediate bearing) splicing complexes characterized in mammalian extracts have likewise been analyzed (48-50). Whereas differences in sample origin and data base completeness complicate the direct comparison of these structures, the reported subunit compositions are generally consistent with the proposed time of complex function. For instance, early acting proteins, such as U1 snRNP factors and many U4/U6.U5 proteins, are present in the yeast penta-snRNP and in the A/B complexes but reduced or absent in the complex C and the Clf1p-RNP structures. Late acting factors, such as the second step proteins Slu7p, Prp16p, and Prp17p and the mRNA release protein, Prp22p, are absent from the earlier complexes but found in Clf1p RNP complex C and/or mammalian C complexes.

The protein and snRNA composition of the Clf1p-RNP is consistent with this complex being an endogenous late stage or postcatalytic spliceosome. The inhibition of pre-mRNA splicing by temperature inactivation of several early acting splicing factors blocks the formation of the Clf1p-RNP, consistent with a "splicing-dependent" origin2 and arguing against this structure arising as an artifact of protein isolation. If truly a late stage spliceosome, transition from complex C to the Clf1p-RNP would be accompanied minimally by the release of the cap binding proteins and the remaining U4/U6.U5-specific proteins. Whereas substrate RNAs would probably be in low abundance or missing altogether, it might be possible to trap such molecules through the use of mutants defective in mRNA or intron release (51, 52). What of the Clf1p-NTC? With the possible exception of Ccf8p, all Clf1p-NTC factors are present in the more complex Clf1p-RNP state. Given this situation, the Clf1p-NTC probably represents either a precursor of the Clf1p-RNP or a splicing complex at the terminal stage of dissociation. Whereas a careful kinetic analysis of complex assembly is needed to distinguish between these alternative origins of the Clf1p-NTC, some support for the latter model is provided by the presence of the stable snRNP proteins Brr2p and Prp8p in the snRNA-free Clf1p-NTC structure.

    ACKNOWLEDGEMENTS

We thank Soo-Chen Cheng, Beate Schwer, and Bertrand Seraphin for providing various yeast strains and antibodies used in this study. We thank Martha Peterson and William Pierce for valuable comments on this manuscript and preliminary characterization of the Clf1p complex by mass spectroscopy, respectively.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant GM42476 (to B. C. R.) and by proteomic support through National Science Foundation Grant EPS-0132295 (to B. L.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed. Tel.: 859-257-5530; Fax: 859-257-1717; E-mail: rymond@uky.edu.

Published, JBC Papers in Press, December 31, 2002, DOI 10.1074/jbc.M210839200

2 Q. Wang and B. C. Rymond, unpublished observations.

    ABBREVIATIONS

The abbreviations used are: snRNA, small nuclear RNA; RNP, ribonucleoprotein; snRNP, small nuclear RNP; TPR, tetratricopeptide repeat; NTC, nineteen complex; HA, hemagglutinin; Tricine, N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Schwer, B. (2001) Nat. Struct. Biol. 8, 113-116[CrossRef][Medline] [Order article via Infotrieve]
2. Staley, J. P., and Guthrie, C. (1998) Cell 92, 315-326[Medline] [Order article via Infotrieve]
3. Kramer, A. (1996) Annu. Rev. Biochem. 65, 367-409[CrossRef][Medline] [Order article via Infotrieve]
4. Ladd, A. N., and Cooper, T. A. (2002) Genome Biol. 3, 1-16
5. Maniatis, T., and Tasic, B. (2002) Nature 418, 236-243[CrossRef][Medline] [Order article via Infotrieve]
6. Burge, C. B., Tuschl, T., and Sharp, P. A. (1999) in The RNA World (Gesteland, R. F. , Cech, T. R. , and Atkins, J. F., eds), 2nd Ed. , Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
7. Collins, C. A., and Guthrie, C. (2000) Nat. Struct. Biol. 7, 850-854[CrossRef][Medline] [Order article via Infotrieve]
8. Galisson, F., and Legrain, P. (1993) Nucleic Acids Res. 21, 1555-1562[Abstract]
9. Abovich, N., Legrain, P., and Rosbash, M. (1990) Mol. Cell. Biol. 10, 6417-6425[Medline] [Order article via Infotrieve]
10. Chung, S., McLean, M. R., and Rymond, B. C. (1999) RNA 5, 1042-1054[Abstract/Free Full Text]
11. Zhang, K., Smouse, D., and Perrimon, N. (1991) Genes Dev. 5, 1080-1091[Abstract]
12. McLean, M. R., and Rymond, B. C. (1998) Mol. Cell. Biol. 18, 353-360[Abstract/Free Full Text]
13. Burnette, J. M., Hatton, A. R., and Lopez, A. J. (1999) Genetics 151, 1517-1529[Abstract/Free Full Text]
14. Chung, S., Zhou, Z., Huddleston, K. A., Harrison, D. A., Reed, R., Coleman, T. A., and Rymond, B. C. (2002) Biophys. Biochem. Acta 1576, 289-297
15. Russell, C. S., Ben-Yehuda, S., Dix, I., Kupiec, M., and Beggs, J. D. (2000) RNA 6, 1565-1572[Abstract/Free Full Text]
16. Ben-Yehuda, S., Dix, I., Russell, C. S., McGarvey, M., Beggs, J. D., and Kupiec, M. (2000) Genetics 156, 1503-1517[Abstract/Free Full Text]
17. Dix, I., Russell, C. S., O'Keefe, R. T., Newman, A. J., and Beggs, J. D. (1998) RNA 4, 1675-1686[Abstract]
18. Chen, C. H., Yu, W. C., Tsao, T. Y., Wang, L. Y., Chen, H. R., Lin, J. Y., Tsai, W. Y., and Cheng, S. C. (2002) Nucleic Acids Res. 30, 1029-1037[Abstract/Free Full Text]
19. Tarn, W. Y., Lee, K. R., and Cheng, S. C. (1993) Mol. Cell. Biol. 13, 1883-1891[Abstract]
20. Tarn, W. Y., Lee, K. R., and Cheng, S. C. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 10821-10825[Abstract]
21. McDonald, W. H., Ohi, R., Smelkova, N., Frendewey, D., and Gould, K. L. (1999) Mol. Cell. Biol. 19, 5352-5362[Abstract/Free Full Text]
22. Puig, O., Caspary, F., Rigaut, G., Rutz, B., Bouveret, E., Bragado-Nilsson, E., Wilm, M., and Seraphin, B. (2001) Methods 24, 218-229[CrossRef][Medline] [Order article via Infotrieve]
23. Kaiser, C., Michaelis, S., and Mitchell, A. (eds) (1994) Methods in Yeast Genetics , Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
24. Boeke, J. D., Trueheart, J., Natsoulis, G., and Fink, G. R. (1987) Methods Enzymol. 154, 164-175[Medline] [Order article via Infotrieve]
25. Gietz, R. D., and Sugino, A. (1988) Gene (Amst.) 74, 527-534[CrossRef][Medline] [Order article via Infotrieve]
26. Blanton, S., Srinivasan, A., and Rymond, B. C. (1992) Mol. Cell. Biol. 12, 3939-3947[Abstract]
27. Umen, J. G., and Guthrie, C. (1995) Genes Dev. 9, 855-868[Abstract]
28. Pikielny, C. W., and Rosbash, M. (1986) Cell 45, 869-877[Medline] [Order article via Infotrieve]
29. Rymond, B. C., and Rosbash, M. (1988) Genes Dev. 2, 428-439[Abstract]
30. Xie, J., Beickman, K., Otte, E., and Rymond, B. C. (1998) EMBO J. 17, 2938-2946[Abstract/Free Full Text]
31. Pikielny, C. W., Rymond, B. C., and Rosbash, M. (1986) Nature 324, 341-345[Medline] [Order article via Infotrieve]
32. Ansari, A., and Schwer, B. (1995) EMBO J. 14, 4001-4009[Abstract]
33. Kolodziej, P. A., and Young, R. A. (1991) Methods Enzymol. 194, 508-519[Medline] [Order article via Infotrieve]
34. Schagger, H., and von Jagow, G. (1987) Anal. Biochem. 166, 368-379[Medline] [Order article via Infotrieve]
35. Gharahdaghi, F., Weinberg, C. R., Meagher, D. A., Imai, B. S., and Mische, S. M. (1999) Electrophoresis 20, 601-605[CrossRef][Medline] [Order article via Infotrieve]
36. Rosenfeld, J., Capdevielle, J., Guillemot, J. C., and Ferrara, P. (1992) Anal. Biochem. 203, 173-179[Medline] [Order article via Infotrieve]
37. Tsai, W. Y., Chow, Y. T., Chen, H. R., Huang, K. T., Hong, R. I., Jan, S. P., Kuo, N. Y., Tsao, T. Y., Chen, C. H., and Cheng, S. C. (1999) J. Biol. Chem. 274, 9455-9462[Abstract/Free Full Text]
38. van Nues, R. W., and Beggs, J. D. (2001) Genetics 157, 1451-1467[Abstract/Free Full Text]
39. Ohi, M. D., Link, A. J., Ren, L., Jennings, J. L., McDonald, W. H., and Gould, K. L. (2002) Mol. Cell. Biol. 22, 2011-2024[Abstract/Free Full Text]
40. Lockhart, S. R., and Rymond, B. C. (1994) Mol. Cell. Biol. 14, 3623-3633[Abstract]
41. Maroney, P. A., Romfo, C. M., and Nilsen, T. W. (2000) Mol. Cell 6, 317-328[Medline] [Order article via Infotrieve]
42. Stevens, S. W., Ryan, D. E., Ge, H. Y., Moore, R. E., Young, M. K., Lee, T. D., and Abelson, J. (2002) Mol. Cell 9, 31-44[Medline] [Order article via Infotrieve]
43. Gottschalk, A., Neubauer, G., Banroques, J., Mann, M., Luhrmann, R., and Fabrizio, P. (1999) EMBO J. 18, 4535-4548[Abstract/Free Full Text]
44. Gottschalk, A., Kastner, B., Luhrmann, R., and Fabrizio, P. (2001) RNA 7, 1554-1565[Abstract/Free Full Text]
45. Weidenhammer, E. M., Ruiz-Noriega, M., and Woolford, J. L., Jr. (1997) Mol. Cell. Biol. 17, 3580-3588[Abstract]
46. Makarova, O. V., Makarov, E. M., and Luhrmann, R. (2001) EMBO J. 20, 2553-2563[Abstract/Free Full Text]
47. Lygerou, Z., Christophides, G., and Seraphin, B. (1999) Mol. Cell. Biol. 19, 2008-2020[Abstract/Free Full Text]
48. Bennett, M., Michaud, S., Kingston, J., and Reed, R. (1992) Genes Dev. 6, 1986-2000[Abstract]
49. Neubauer, G., King, A., Rappsilber, J., Calvio, C., Watson, M., Ajuh, P., Sleeman, J., Lamond, A., and Mann, M. (1998) Nat. Genet. 20, 46-50[CrossRef][Medline] [Order article via Infotrieve]
50. Jurica, M. S., Licklider, L. J., Gygi, S. R., Grigorieff, N., and Moore, M. J. (2002) RNA 8, 426-439[Abstract/Free Full Text]
51. Arenas, J. E., and Abelson, J. N. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 11798-11802[Abstract/Free Full Text]
52. Company, M., Arenas, J., and Abelson, J. (1991) Nature 349, 487-493[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.